Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Oriana Borquez-Ojeda"'
Autor:
Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, Fang Du, Jinrong Qu, Jagrutiben Chaudhari, Keyur Thummar, Mingzhu Zhu, Ling-bo Shen, Melanie Hall, Paridhi Gautam, Yongzeng Wang, Brigitte Sénéchal, Devanjan Sikder, Prasad S. Adusumilli, Renier J. Brentjens, Kevin Curran, Mark B. Geyer, Sham Mailankhody, Roisin O’Cearbhaill, Jae H. Park, Craig Sauter, Susan Slovin, Eric L. Smith, Isabelle Rivière
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 377-387 (2021)
With the US Food and Drug Administration (FDA) approval of four CD19- and one BCMA-targeted chimeric antigen receptor (CAR) therapy for B cell malignancies, CAR T cell therapy has finally reached the status of a medicinal product. The successful manu
Externí odkaz:
https://doaj.org/article/ac2a507ac1554df1b9bab28f312a4318
Autor:
Eric L. Smith, Brigitte Senechal, Craig S. Sauter, Jolanta Stefanski, Fang Du, Prasad S. Adusumilli, Susan F. Slovin, Ling-bo Shen, Devanjan S. Sikder, Jagrutiben Chaudhari, Kevin J. Curran, Renier J. Brentjens, Keyur Thummar, Yongzeng Wang, Melanie Hall, Xiuyan Wang, Isabelle Riviere, Roisin E. O'Cearbhaill, Mark B. Geyer, Sham Mailankhody, Mingzhu Zhu, Jae H. Park, Paridhi Gautam, Jinrong Qu, Oriana Borquez-Ojeda
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 377-387 (2021)
With the US Food and Drug Administration (FDA) approval of four CD19- and one BCMA-targeted chimeric antigen receptor (CAR) therapy for B cell malignancies, CAR T cell therapy has finally reached the status of a medicinal product. The successful manu
Autor:
Raymond Yeh, Shirley Bartido, Malgorzata Olszewska, Clare Taylor, Oriana Borquez-Ojeda, Michel Sadelain, Vanessa Capacio, Isabelle Riviere, James Hosey, Mark Przybylowski, Daniel Hollyman, Renier J. Brentjens, Jolanta Stefanski
Publikováno v:
Journal of Immunotherapy. 32:169-180
On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patient
Publikováno v:
Vaccine. 25:5013-5024
The use of plasmid DNA as vaccines for the treatment of cancer and infectious diseases is on the rise. In order to facilitate the manufacture of clinical-grade plasmid DNA for Phase I clinical trials, we developed a process whereby >200 mg plasmid co
Autor:
Bing Zhang, Oriana Borquez-Ojeda, Roberto Sanchez, David W. Golde, Alicia Pedraza, Juan M. Cárcamo
Publikováno v:
Molecular and Cellular Biology. 24:6645-6652
Dietary vitamin C is essential for humans, primates, guinea pigs, and several other animals and insects that lack l-gulono-γ-lactone oxidase, the final enzyme in its biosynthetic pathway from glucose (25). Under physiological conditions, vitamin C p
Autor:
Hediye Erdjument-Bromage, Paul Tempst, Jian Chen, David W. Golde, Juan M. Cárcamo, Oriana Borquez-Ojeda
Publikováno v:
Proceedings of the National Academy of Sciences. 100:14000-14005
Basement membrane matrix proteins are known to up-regulate granulocyte–macrophage colony-stimulating factor (GM-CSF) signaling in neutrophils and mononuclear phagocytes, but the mechanisms involved are poorly understood. We used the intracellular p
Publikováno v:
Biochemistry. 41:12995-13002
Extracellular stimuli signal for activation of the transcription factor NFkappaB, leading to gene expression regulating processes involved in immune responses, inflammation, and cell survival. Tumor necrosis factor-alpha (TNFalpha) activates NFkappaB
Publikováno v:
Blood. 99:3205-3212
Vitamin C is present in the cytosol as ascorbic acid, functioning primarily as a cofactor for enzymatic reactions and as an antioxidant to scavenge free radicals. Human granulocyte macrophage–colony-stimulating factor (GM-CSF) induces an increase i
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Autor:
Marco L. Davila, Shirley Bartido, Dan Douer, Mitsu Fink, James Hosey, Maria E. Arcila, Kevin J. Curran, Michel Sadelain, Diana C. G. Bouhassira, Gail J. Roboz, Xiuyan Wang, Jolanta Stefanski, Maher Youssif, Elizabeth Halton, Mark Satter, Stephen S. Chung, Yongzeng Wang, Oriana Borquez-Ojeda, Sergio Giralt, Malgorzata Olszewska, Himaly Shinglot, Jae H. Park, Jinrong Qu, Mithat Gonen, Isabelle Riviere, Peter Maslak, Qing He, Renier J. Brentjens, Mark G. Frattini, Teresa Wasielewska, Yvette Bernal, Hilda Quintanilla
Publikováno v:
Science translational medicine. 6(224)
We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response
Autor:
Cyrus V. Hedvat, Shirley Bartido, Mark G. Frattini, Marco L. Davila, Lindsay G. Cowell, Teresa Wasielewska, Clare Taylor, Joseph G. Jurcic, Kevin J. Curran, Yvette Bernal, Jolanta Stefanski, Qing He, Malgorzata Olszewska, Ivelise Rijo, Jae H. Park, Peter G. Steinherz, Renier J. Brentjens, Xiuyan Wang, Rachel Kobos, Oriana Borquez-Ojeda, Isabelle Riviere, Jinrong Qu, Peter Maslak, Michel Sadelain, Todd L. Rosenblat
Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis. Only those patients able to achieve a second remission with no minimal residual disease (MRD) have a hope for long-term survival in the context of a subsequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdbe9884d936f4db3e49f325a972fe18
https://europepmc.org/articles/PMC3742551/
https://europepmc.org/articles/PMC3742551/